Genetic

Travere Therapeutics Reports First Quarter 2024 Financial Results

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, Total, Risk, Ligand Pharmaceuticals, European Commission, Research, UPCR, Webcast, HCU, IND, EGFR, PDUFA, SIMD, Civil service commission, Diagnosis, PMDA, GAAP, CMA, Congress, Table, PROTECT, Priority review, Food, Abstract, FSGS, Income tax, CSL Vifor, Quarter, Medication, Therapy, SAN, Plasma, Urine, International, Safety, Proteinuria, ANNA, Immunoglobulin A, Homocysteine, Investigational New Drug, Society, Shanda, New Drug Application, Genetic, European, Disease, Patient, Quality of life (healthcare), IPR, Bank statement, Growth, Pharmaceutical industry

Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.

Key Points: 
  • Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.
  • Travere Therapeutics will host a conference call and webcast today, Monday, May 6, 2024, at 4:30 p.m.
  • ET to discuss company updates as well as first quarter 2024 financial results.
  • The Company believes that these non-GAAP financial measures are helpful in understanding its past financial performance and potential future results.

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
Martedì, Maggio 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

Lyric and Concert Expand Partnership to Deliver Laboratory Payment Accuracy Solution

Retrieved on: 
Mercoledì, Maggio 1, 2024
Genetic, Partnership, Therapy, Trust, Lyric, COVID-19, Growth, Concert, Online shopping

PHILADELPHIA, May 1, 2024 /PRNewswire/ -- Lyric, an AI-first leader in payment accuracy, has expanded its partnership with Concert to deliver payment accuracy across a rapidly expanding set of advanced and routine laboratory tests, the companies announced today.

Key Points: 
  • PHILADELPHIA, May 1, 2024 /PRNewswire/ -- Lyric, an AI-first leader in payment accuracy, has expanded its partnership with Concert to deliver payment accuracy across a rapidly expanding set of advanced and routine laboratory tests, the companies announced today.
  • Together, Concert and Lyric will deliver a technology solution for laboratory payment accuracy that is transparent, reduces the chance for errors, and is minimally abrasive.
  • The solution will deliver Concert's claim editing—based on its integrated payment policy and medical policy content—through a seamless customer experience.
  • Lyric and Concert first partnered in 2023 to deliver an integrated genetic test management solution.

Sheppard Mullin Welcomes IP Partner Alex Chung in Washington D.C.

Retrieved on: 
Mercoledì, Aprile 24, 2024
Professional Services, Patent Law, Health, Legal, Pharmaceutical, Biotechnology, University, Bangladesh Technical Education Board, IP, CRISPR, RNA interference, NIH, Intellectual property, Perkins Coie, Monoclonal antibody, Genetic, RNA, Research, Seoul National University, Genetic engineering, AAV, B cell, Patent, ADC, Chung, TPD, Conjugation, National university

Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho “Alex” Chung, Ph.D. has joined the firm’s Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at Perkins Coie LLP.

Key Points: 
  • Sheppard, Mullin, Richter & Hampton LLP is pleased to announce that Kwan-Ho “Alex” Chung, Ph.D. has joined the firm’s Intellectual Property practice group and Life Sciences industry team in Washington, D.C. Chung was most recently a partner at Perkins Coie LLP.
  • Chung’s move to Sheppard Mullin follows the recent hire of life sciences IP partner, Jaime Choi , Ph.D., in February.
  • His extensive experience includes procuring, managing, evaluating, enforcing and defending patents and providing clients strategic IP counsel.
  • “Alex is another pillar in our strategic effort to continue to grow our Life Sciences team,” said Luca Salvi, chair of Sheppard Mullin.

Prevent Blindness Declares May as First-ever Inherited Retinal Disease (IRD) Genetic Testing Awareness Month

Retrieved on: 
Mercoledì, Aprile 24, 2024
Education, Paratriathlon, University, Blood, Birth defect, Retina, RP, Social media, Diagnosis, Stargardt disease, Stargardt, Marketing, Strabismus, Genetic, Johnson & Johnson, Gene, Spark Therapeutics, Choroid, Research, Visual impairment, Genetic testing, Pediatric ophthalmology, Disease, Visual Science, Patient, Eye, Cone dystrophy, MBA, Vision, Student, Therapy, Organization, IRD, Pharmaceutical industry

CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness, the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative. The group is providing a variety of tools to promote awareness and education for IRDs and the importance of genetic testing, including a free webinar, expert and patient videos, shareable social media graphics, and fact sheets in English and Spanish. IRD Genetic Testing Awareness Month is supported by funding from Johnson & Johnson, and Spark® Therapeutics.

Key Points: 
  • Prevent Blindness expands IRD and genetic testing awareness initiative to educate patients on various forms of IRDs, and the importance of genetic testing to confirm diagnosis and possible treatments.
  • CHICAGO, April 24, 2024 /PRNewswire-PRWeb/ -- Prevent Blindness , the nation's leading nonprofit eye health and safety organization, has designated May as "Inherited Retinal Disease (IRD) Genetic Testing Awareness Month," expanding its previous IRD and Genetic Testing Awareness Week initiative.
  • ET, the National Center for Children's Vision and Eye Health at Prevent Blindness will be hosting the free webinar, " Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases ."
  • To register for the "Pathway to Diagnosis: Genetic Testing for Inherited Retinal Diseases" webinar, visit PreventBlindness.org/IRD-webinar-2024.

Ascential Medical & Life Sciences Appoints Anupam Girdhar as Divisional CEO

Retrieved on: 
Martedì, Aprile 16, 2024
NACS, Genetic, Ideation, Baxter International, Automation, Thermo Fisher Scientific, Marketing, Clinical nutrition, Genetic testing, Ascential, Organization, Growth, Engineering, Management

SAN DIEGO, April 16, 2024 /PRNewswire/ -- Ascential Medical & Life Sciences today announced the appointment of Anupam Girdhar as divisional CEO. A business leader with 25 years of operational and strategic experience, Mr. Girdhar has managed complex life science tools and medical devices businesses. He has a proven track record fostering growth and cultivating top-tier organizations and will work towards positioning Ascential Medical & Life Sciences for lasting success.

Key Points: 
  • With more than two decades of relevant experience, Girdhar has held leadership positions at Thermo Fisher Scientific and Baxter Healthcare
    SAN DIEGO, April 16, 2024 /PRNewswire/ -- Ascential Medical & Life Sciences today announced the appointment of Anupam Girdhar as divisional CEO.
  • He has a proven track record fostering growth and cultivating top-tier organizations and will work towards positioning Ascential Medical & Life Sciences for lasting success.
  • "Anupam has an impressive background that combines technical and business expertise and a proven reputation in the medical and life sciences industry," said Jeff Moss, CEO of Ascential Technologies.
  • Ascential Medical & Life Sciences provides end-to-end capabilities for complex medical device assembly and total commercialization services from ideation to scaled manufacturing.

ACMG Foundation for Genetic and Genomic Medicine Elects Four Highly Accomplished Medical Genetics Professionals to its Board of Directors

Retrieved on: 
Giovedì, Aprile 11, 2024
Education, Disorder, Rady Children's Hospital, Entrepreneurship, Doctor of Philosophy, Pathology, ACMG, Medical director, American Academy, Veterinarian, Myriad Genetics, FACMG, Drug, Genetic testing, Baylor College of Medicine, Distinguishing, International HapMap Project, New York University, Clinical Pediatrics, National academy, Hospital, Hispanic, Book, Health, American Medical Association, Research, Pediatrics (journal), Mental health, Master of Science, Genetic distance, Pediatrics, Women's health, School, Washington State University, Society, Cancer, Partnership, Genomics, American College, Policy, Genetic, Disability studies, Developmental Biology (journal), Friends, Patient, MED, MBA, Baylor University

The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.

Key Points: 
  • The ACMG Foundation is a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice.
  • The board members are active participants, serving as advocates for the ACMG Foundation and for advancing its policies and programs.
  • ACMG Foundation President Nancy J. Mendelsohn, MD, FACMG said, "We are pleased to welcome these four new members to the ACMG Foundation Board of Directors.
  • "I am honored for the opportunity to serve the ACMG again through participation in the Foundation Board of Directors.

Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

Retrieved on: 
Giovedì, Aprile 4, 2024
Homocysteine, Homocystinuria, Caregiver, SAN, HCU, Society, Treatment, Therapy, Genetic, SIMD, Pharmaceutical industry

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.

Key Points: 
  • SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present eight posters in classical homocystinuria (HCU) at Society for Inherited Metabolic Disorders (SIMD) in Charlotte, North Carolina from April 14-17, 2024, and Genetic Metabolic Dieticians International (GMDI) in Charlotte, North Carolina from April 17-20, 2024.
  • At SIMD and GMDI, the Company will present the trial design of the pivotal Phase 3 HARMONY Study of pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of classical HCU.
  • Additionally, the Company will share insights on the development of an innovative tool used for dietary management and monitoring in the Phase 3 HARMONY Study and open-label extension ENSEMBLE Study, and the positive results from cohort 6 in the placebo-controlled Phase 1/2 COMPOSE Study of pegtibatinase in classical HCU.
  • “Classical HCU is an isolating and devastating rare disorder with very limited treatment options, including adherence to highly restrictive diets, leaving patients and their caregivers with immense challenges,” said Jula Inrig, M.D., chief medical officer of Travere Therapeutics.

Natalia Gomez-Ospina, MD, PhD is the Recipient of the 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
Mercoledì, Marzo 13, 2024
Research, Partner, Brain, B cell, FACMG, Gaucher's disease, Assistant, Pediatric Research, American Journal, Patient, Medical genetics, DSM-IV codes, Glycogen storage disease, System, Young Scientist Award, Gene therapy, Doctor of Philosophy, Stanford University, Protein, Genome, American College, Mucopolysaccharidosis, Genomics, Society, Hospital, Genetic, Cell, Young, Genetic distance, Hurler syndrome, Lucile Packard Children's Hospital

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Natalia Gomez-Ospina, MD, PhD is the recipient of the ACMG Foundation for Genetic and Genomic Medicine's 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award—the "Watson Award"—named for the American College of Medical Genetics and Genomics first and longstanding executive director, Michael S. Watson, MS, PhD, FACMG.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Natalia Gomez-Ospina, MD, PhD is the recipient of the ACMG Foundation for Genetic and Genomic Medicine's 2024 Dr. Michael S. Watson Genetic and Genomic Medicine Innovation Award—the "Watson Award"—named for the American College of Medical Genetics and Genomics first and longstanding executive director, Michael S. Watson, MS, PhD, FACMG.
  • "I am honored to receive this award in recognition of my dedication to advancing genetic and genomic medicine and my commitment to making a positive difference in the lives of patients with genetic diseases.
  • This award affirms the need for innovative approaches to treat such diseases and the immense potential that genome editing has in this regard.
  • "Dr. Gomez-Espina is a promising physician-scientist whose work is befitting the Dr. Michael Watson Genetic and Genomic Medicine Innovation Award, an award that honors an individual whose work has had a significant impact on genetic and genomic medicine.

Acclaimed Clinical Geneticist Dr. Bruce Korf Honored with 2024 David L. Rimoin Lifetime Achievement Award in Medical Genetics from the ACMG Foundation for Genetic and Genomic Medicine

Retrieved on: 
Mercoledì, Marzo 13, 2024
Department of Defence, Friends, Patient, Medical genetics, Travel, Child, Neurofibromatosis, Practice, UAB, Gene expression, Dean (education), Education, Rockefeller University, Seed, NF, NIH, American College, Pediatrics, Person, Karyotype, MD–PhD, Boston Children's Hospital, Principle, Birmingham School of Law, Neurology, FACOG, Genetics, Cornell University, American Journal, Research, Hospital, University, Human genetics, Student, Publication, DRS, ACMG, Book, Genetic distance, DSM-IV codes, Diagnosis, FACMG, Empathy, Montefiore Medical Center, Distinguishing, Mouse, Hope, Doctor of Philosophy, Life, Genetic, Bangladesh Technical Education Board, Physician, Nursing

BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.

Key Points: 
  • BETHESDA, Md., March 13, 2024 /PRNewswire/ -- Renowned clinical geneticist Bruce Korf, MD, PhD, FACMG, has been named the recipient of the 2024 ACMG Foundation for Genetic and Genomic Medicine's David L. Rimoin Lifetime Achievement Award in Medical Genetics.
  • Dr. Korf is an authentic, kind and ethical human being whose life and career in medical genetics are unparalleled."
  • "Dr. Korf's extraordinary accomplishments in clinical genetics, neurofibromatosis, and genomics, as well as his dedication to education make him a well deserving winner of the David Rimoin Lifetime Achievement Award.
  • Before he died, David appreciated the opportunity to work with Bruce first-hand in the editing of Principles and Practice of Medical Genetics as well as on numerous committees for the ACMG.